ADVERSE DRUG REACTION

A woman who couldn’t speak: report of methotrexate neurotoxicity

P Szawarski, C S Chapman

The association between methotrexate therapy and idiosyncratic neurological complications is well recognised in children. This case illustrates the importance of considering the diagnosis of methotrexate toxicity in an adult patient with behavioural and speech disturbances, who received it by intrathecal route only and in whom the only indicator was an abnormal electroencephalographic study.

The differential diagnosis of neurological abnormalities in patients with haematological malignancy undergoing chemotherapy is very broad. Vascular, infectious, metabolic, malignant, and drug related causes need to be considered and investigated. Often diagnosis is achieved by gradual elimination of various possibilities. In this case report we present a patient whose neurological illness was felt to represent methotrexate neurotoxicity. The nature and possible causes of neurotoxicity of this drug are discussed and the diagnostic difficulties are illustrated.

CASE REPORT

A 22 year old Asian woman was diagnosed with pre-B acute lymphoblastic leukaemia (ALL). Her white cell count was 22.3 x 10^9/L, haemoglobin 8.8 g/L, platelets 27 x 10^9/L with blast count of 4.35. Her folate was within normal range. She was treated according to the UK ALL XII protocol. During induction she required intermittent courses of antibiotics for treatment of neutropenic fever. She experienced no problems with effusions, ascites, or renal impairment.

At presentation she was noted to have 3 cm hepatomegaly, which resolved within the first week of treatment. On day 26 of phase 2 of induction, after completion of intrathecal methotrexate at a total cumulative dose of 62.5 mg given over five courses, she complained of mild headache and difficulty finding words. Both symptoms were of sudden onset.

On examination, stuttering or staccato speech with mild expressive dysphasia were noted. Otherwise neurological examination was normal. There was a brief improvement followed by a further deterioration 24 hours later with progressive dysphasia, headache, behavioural disturbances (food refusal, crying, and refusing examination), and raised temperature, which never exceeded 38°C. No focal weakness, paraesthesiae, fundal changes, or meningism were present. Reflexes and tone were normal. There appeared to be some truncal and limb ataxia, which was difficult to verify because of progressive behavioural disturbance. Dysphasia, which initially was only expressive, progressed to total aphasia. Tongue dyspraxia was noted. Dysphasia took the form of hesitancy, progressive stammer, and a progressive inability to complete words. There were no features indicative of a frontal lesion.

Computed tomography with intravenous contrast was performed showing normal anatomy. Magnetic resonance imaging (MRI) including T2 axial, T1 coronal and contrast T1 axial and coronal images, performed four days after the onset of symptoms showed no abnormalities. In particular there was no evidence of ischaemia, mass lesions, meningeal enhancement, or cortical signal abnormalities. Cerebrospinal fluid protein concentration was 0.29 g/L, glucose was 2.7 mmol/L, and microscopy showed no leukaemic cells. Polymerase chain reactions for viral specific DNA performed on a cerebrospinal fluid sample, were negative for herpes simplex DNA, varicella zoster DNA, cytomegalovirus, enterovirus, herpes 6 DNA, and herpes 7 DNA. In view of the fever, acyclovir, amphotericin and broad spectrum antibiotics were given, with initial lack of response.

Gradually her temperature settled with no impact on neurological symptoms. Gram negative bacilli were isolated from the Hickman line. In view of the persistence of behavioural and speech disturbance with paucity of neurological findings, a psychiatric opinion was sought. Assessment raised the possibility of mutism attributable to dissociative state or conversion disorder. Repeat MRI with MR venography and axial FLAIR images performed at 14 days was entirely normal. An EEG was performed showing excessive bilateral slow wave activity, suggestive of diffuse cerebral dysfunction compatible with diagnosis of infective, neoplastic, or metabolic encephalopathy.

We have found no evidence of leukaemia in the cerebrospinal fluid sample. Negativity of viral polymerase chain reactions and lack of response due to broad antiviral, antifungal, antibiotic treatment does not support the infective cause of the neurological symptoms. Metabolic causes were considered. Her electrolytes and folate were within normal ranges. Magnesium was low at 0.72 and was corrected. There was no renal or hepatic failure. She had not received high dose intravenous methotrexate. The diagnosis of methotrexate induced encephalopathy attributable to intrathecal methotrexate was made by exclusion.

DISCUSSION

Intrathecal methotrexate is important in management of ALL in prevention of recurrence in the central nervous system. Apart from its use in haematology and oncology the drug has also become one of the cornerstones of therapy of autoimmune conditions. Although pulmonary and hepatic toxicity are more common, damage to the nervous system is particularly worrying because of potentially significant disability. Its likelihood may be increased when methotrexate is used at high doses such as in treatment of ALL.

Neurotoxicity relating to use of methotrexate is well recognised. It has mostly been reported in children. We are not aware of any large studies of acute methotrexate neurotoxicity in the adult population. Massekeil and others reported acute tetraparesis and motoric aphasia with...
hypointense white matter signal on MRI 10 days after high
dose intravenous methotrexate with prior intrathecal therapy
for diffuse large B cell lymphoma in an adult. Another adult
patient developed gradual onset of dysarthria and incoordi-
nation with scanning dysarthria and buccofacial dyskinesia
but no other neurological abnormality after oral methotrex-
ate for cutaneous T cell lymphoma. Acute and transient
neurological signs including confusion, slurred speech, and
left hemiparesis attributable to methotrexate has been
reported in a patient treated for pre-B ALL. In this case
MRI showed restrictive diffusion in frontoparietal white
matter and splenium of corpus callosum. The T2 FLAIR
images were normal.

The aetiology of methotrexate toxicity remains uncertain.
Its often transient nature with predilection for specific parts
of the central nervous system would be compatible with
small vessel ischaemia. However, this would be probably
reflected in the MRI images. A review of possible mechan-
isms behind methotrexate neurotoxicity points towards
several metabolic pathways affected by the drug. Methotrexate
inhibits dihydrofolate reductase, which through facilitating
purine and thymidine synthesis is important in synthesis of DNA and RNA in replicating cells. Its interference with folate metabolism also results in raised homocysteine and sulphur containing aminoacids levels. The latter have excitatory effects by causing release of glutamate and aspartate and through direct excitatory action at NMDA receptor. This can promote seizure activity. Homocysteine is toxic to the epithelial cells, which can lead to ischaemic events, but whether sufficient plasma concentrations can be achieved to cause this after intrathecal therapy is question-
able. Methotrexate also interferes with the bioppterin path-
way, which is responsible for synthesis of important neurotransmitters: serotonin and dopamine. Deficiency of these would result in hypokinesia, hypotonia, limb rigidity, swallowing difficulties, and temperature regulation abnorm-
alities. Understanding the possible mechanisms behind methotrexate toxicity takes us closer to being able to offer treatment to affected patients. Indeed successful use of dextromethorphan, a non-competitive NMDA receptor antagonist has been reported offering confirmation of some of the postulated mechanisms behind toxicity of methotrexate.

CONCLUSIONS

This case highlights the importance of diagnosis of metho-
trexate neurotoxicity in adult patients. Most cases reported so
far (in children) have been on patients receiving oral or high
dose regimens with leucovorin rescue. In this case only
intrathecal therapy was administered. This case also illus-
trates the value of performing an EEG when MRI and
computed tomographic findings are normal. Finally, the
incomplete knowledge of a drug that has been in use for
some 50 years is illustrated. With its increased use the
mechanisms behind neurotoxicity need to be elucidated to
maximise patient safety and reduce morbidity. Three months
after completion of methotrexate, our patient was making a
slow recovery. Mild ataxia was still present together with
some expressive dysphasia, but she was able to converse.
Full, spontaneous recovery from methotrexate toxicity is
possible over a variable period of time.

authors' affiliations

P Szawarski, Respiratory Medicine, Glenfield General Hospital,
Leicester, UK
C S Chapman, Haematology Department, Leicester Royal Infirmary,
Leicester, UK

Correspondence to: Dr C S Chapman, Haematology Department,
Sandringham Building, Leicester Royal Infirmary, Infirmery Square,
Leicester LE1 5WW, UK; claire.chapman@uhl-tr.nhs.uk

Submitted 29 December 2003
Accepted 14 July 2004

REFERENCES

1 Medical Research Council working party on Leukaemia in Adults. UKALL XII
protocol for adult patients with ALL under 56 years of age. May, 1995.
with B-percursor acute lymphoid leukaemia: an association with intermediate-
dose intrathecal methotrexate and intrathecal triple therapy—a Pediatric
3 Nigro IL, Di Cataldo A, Schilirio G. Acute neurotoxicity in children with B-
lineage acute lymphocytic leukaemia (B-ALL) treated with intermediate risk
4 Massenkeil G, Speth-Schwab E, Floth B, et al. Transient tetraparesis after
intrathecal and high dose systemic methotrexate. Ann Hematol
1998;77:239–42.
5 Aplin CG, Russell-Jones R. Acute dysarthria induced by low dose methotrexate
therapy in a patient with erythrodermic cutaneous T-cell lymphoma: an
7 Yezmez S, Becker A, Bode U, et al. Biochemical and clinical aspects of
8 Drachtman RA, Cole PD, Golden CS, et al. Dextromethorphan is effective in
the treatment of subacute methotrexate neurotoxicity. Pediatr Hemat Oncal
A woman who couldn't speak: report of methotrexate neurotoxicity

P Szawarski and C S Chapman

*Postgrad Med J* 2005 81: 194-195
doi: 10.1136/pgmj.2003.018267

Updated information and services can be found at:
http://pmj.bmj.com/content/81/953/194

These include:

**References**
This article cites 7 articles, 2 of which you can access for free at:
http://pmj.bmj.com/content/81/953/194#BIBL

**Email alerting service**
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

**Topic Collections**
Articles on similar topics can be found in the following collections
Chemotherapy (38)

**Notes**

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/